




Searching News Database: antibody-drug conjugate
HSMN NewsFeed - 23 May 2024
SystImmune, Inc. Announces the Appointment of Dr. Jonathan Cheng as New Chief Medical Officer
SystImmune, Inc. Announces the Appointment of Dr. Jonathan Cheng as New Chief Medical Officer
HSMN NewsFeed - 8 Dec 2022
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
HSMN NewsFeed - 22 Jun 2022
Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer
Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer
HSMN NewsFeed - 27 Sep 2021
Japan's MHLW Approves PADCEV(R) (enfortumab vedotin) for Advanced Urothelial Cancer
Japan's MHLW Approves PADCEV(R) (enfortumab vedotin) for Advanced Urothelial Cancer
HSMN NewsFeed - 8 Jun 2021
Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
HSMN NewsFeed - 29 Mar 2021
Phoenix Molecular Designs Appoints Biotech Powerhouse, Michael Varney, Ph.D., to its Advisory Board
Phoenix Molecular Designs Appoints Biotech Powerhouse, Michael Varney, Ph.D., to its Advisory Board
HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
HSMN NewsFeed - 29 Aug 2019
AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
HSMN NewsFeed - 29 Jan 2019
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
HSMN NewsFeed - 1 Oct 2018
Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
HSMN NewsFeed - 12 Sep 2018
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief
HSMN NewsFeed - 24 Jul 2018
Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders
HSMN NewsFeed - 14 May 2018
GT Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company
GT Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company
HSMN NewsFeed - 26 Apr 2018
Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's Board of Directors
Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's Board of Directors
HSMN NewsFeed - 24 Apr 2018
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors
HSMN NewsFeed - 29 Aug 2017
Sorrento Therapeutics, Inc. Submits NDA For ZTlido(TM) Next-Generation Lidocaine Patch
Sorrento Therapeutics, Inc. Submits NDA For ZTlido(TM) Next-Generation Lidocaine Patch
HSMN NewsFeed - 1 Apr 2015
ImmunoGen, Inc. Appoints Anna Berkenblit, MD, MMSc Vice President and Chief Medical Officer
ImmunoGen, Inc. Appoints Anna Berkenblit, MD, MMSc Vice President and Chief Medical Officer
HSMN NewsFeed - 6 Jan 2015
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments
HSMN NewsFeed - 18 Jun 2014
Oxford BioTherapeutics Appoints Dr Keith E Wilson as Chief Scientific Officer
Oxford BioTherapeutics Appoints Dr Keith E Wilson as Chief Scientific Officer
HSMN NewsFeed - 31 Jan 2014
ImmunoGen, Inc. Appoints Eric Guempel as Vice President of Product Strategy and Program Management
ImmunoGen, Inc. Appoints Eric Guempel as Vice President of Product Strategy and Program Management
HSMN NewsFeed - 9 Jan 2014
Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors
Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors
HSMN NewsFeed - 8 Jan 2014
Sorrento Therapeutics Appoints Amar Singh as Executive Vice President and Chief Business Officer
Sorrento Therapeutics Appoints Amar Singh as Executive Vice President and Chief Business Officer
HSMN NewsFeed - 20 Nov 2013
ImmunoGen, Inc. Announces Approval of Roche’s Kadcyla(R) in the European Union
ImmunoGen, Inc. Announces Approval of Roche’s Kadcyla(R) in the European Union
HSMN NewsFeed - 14 Nov 2013
Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology
HSMN NewsFeed - 8 Oct 2013
Molecular Templates Announces $8.5M Series C Financing and $10.6M Grant Funding
Molecular Templates Announces $8.5M Series C Financing and $10.6M Grant Funding
HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
HSMN NewsFeed - 6 Mar 2012
CytomX Therapeutics Appoints Hoyoung Huh, M.D., Ph.D., Chairman of Board of Directors
CytomX Therapeutics Appoints Hoyoung Huh, M.D., Ph.D., Chairman of Board of Directors
HSMN NewsFeed - 30 Aug 2011
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
HSMN NewsFeed - 17 Jun 2011
Seattle Genetics Announces Promotion of Eric Dobmeier to Chief Operating Officer
Seattle Genetics Announces Promotion of Eric Dobmeier to Chief Operating Officer
HSMN NewsFeed - 13 Oct 2009
Seattle Genetics Names Head of Commercial and Announces Management Promotion
Seattle Genetics Names Head of Commercial and Announces Management Promotion
HSMN NewsFeed - 30 Mar 2009
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
HSMN NewsFeed - 20 Mar 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
HSMN NewsFeed - 19 Sep 2007
CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
HSMN NewsFeed - 27 Mar 2007
Seattle Genetics Announces Extension of Antibody-Drug Conjugate Collaboration with Genentech
Seattle Genetics Announces Extension of Antibody-Drug Conjugate Collaboration with Genentech
HSMN NewsFeed - 13 Feb 2007
Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs
Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs
HSMN NewsFeed - 8 Jan 2007
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
Additional items found! 17

Members Archive contains
17 additional stories matching:
antibody-drug conjugate
(Password required)
antibody-drug conjugate
(Password required)